Lushang Freda Pharmaceutical Co., Ltd.SSE: 600223

Report for Q3 2025

Oct 28, 2025 · Issued by Lushang Freda Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 28, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-105

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Lushang Freda Pharmaceutical Co., Ltd. on 6ix

Earlier from Lushang Freda Pharmaceutical

Announcement on Transfer of 100% Equity in Wholly-owned Subsidiary Shandong Lushang Inzone Commercial Management Co., Ltd. and Related Party TransactionOct 11, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025Sep 20, 2025
Announcement on Convening the 2025 Semi-annual Performance BriefingAug 22, 2025
Announcement on Implementation of Dividend Distribution for 2024Jul 17, 2025
Announcement on Resolution of the 2024 Annual General MeetingJun 26, 2025

Later from Lushang Freda Pharmaceutical

Announcement on Resolutions of the 5th Extraordinary Meeting of the 12th Board of Directors in 2025Dec 30, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Jan 15
Announcement on the Ongoing Risk Assessment Report of Shandong Commercial Group Finance Co., Ltd.Apr 3
Announcement on Convening the 2025 Annual Performance BriefingApr 28
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Shandong JurisdictionMay 13

All Lushang Freda Pharmaceutical news releases

Follow Lushang Freda Pharmaceutical into a list and get an email when it puts out news.

Follow Lushang Freda Pharmaceutical